Literature DB >> 29462752

A rare case report of a typical variant ossifying fibromyxoid tumor (OFMT), located in the retroauricular perimastoid region.

Theodoros Varakliotis1, Gianluca Bellocchi2, Alberto Eibenstein3, Gilberto Acquaviva2, Francesco Casorati2.   

Abstract

INTRODUCTION: Ossifying fibromixoid tumor of soft parts (OFMT) is a rare soft tissue and bone tumor. In its classic form, is considered benign, nevertheless aggressive clinical behaviour tumors with a different cytoarchitectural features of a malignant variant, have been described.The classification contains "typical", "atypical" and "malignant" variants.
METHODS: A CT ear scan without contrast enhancement was carried out (October 2015), with coronal, sagittal and 3D reconstructions. It was decided the removal of the neoformation with a simple dissection.
RESULTS: In this report, we present a case of a typical variant OFMT localized in the retroauricular perimastoid region, with mastoid bone cortex not involved.
CONCLUSIONS: Considering the extreme rarity of this "enigmatic" tumor which displays an uncertain line of differentiation, renders the differential diagnosis a true challenge.
Copyright © 2018 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  OFMT; Ossifying fibromixoid tumor; Perimastoid region; Soft tissue and bone tumor

Year:  2018        PMID: 29462752      PMCID: PMC5832672          DOI: 10.1016/j.ijscr.2018.02.017

Source DB:  PubMed          Journal:  Int J Surg Case Rep        ISSN: 2210-2612


Introduction

Ossifying fibromyxoid tumor of soft parts (OFMT) is a rare soft tissue and bone tumor, described for the first time in 1989 by Enzinger et al. [1], which prevalently affects the subcutaneus tissue of extremities and trunk, although other body sites have been reported, such as the mediastinum [2] and neck [3]. It has an uncertain histopathogenesis and is characterized by a peripheral bone shell embedded in a fibromyxoid matrix, which tends to have a rough, small round cell proliferation with a very low mitotic activity. In its classic form, it is considered benign, nevertheless aggressive clinical behaviour tumors with a different cytoarchitectural features of a malignant variant, have been described[[4], [5], [6]]. Folpe and Weiss proposed a classification with “typical”, “atypical” and “malignant” variants [4] and affects males to females at a ratio of approximately 1.5:1, with a median age of 50 years [7]. In this report, we present a case of a typical variant OFMT, localized in the retroauricular perimastoid region, in line with the SCARE criteria [8].

Case report and results

A 31 years old patient presented in the ENT department, on November 2015, reporting a slowly growing mass behind his right ear. The physical examination revealed a solid mass, painless to palpation, absence of ulcers or any other skin lesions, with the dimensions of approximately 2 cm, in the right perimastoid region. Otoscopy was normal, also audiometry did not revealed any abnormalities, such as conductive hearing loss. The medical history hasn’t revealed any other co-morbidities and/or cronic diseases. A CT ear scan without contrast enhancement was carried out (October 2015), with coronal, sagittal and 3D reconstructions (Fig. 1). The exam revealed a right perimastoid mass formation (2.2 × 1.2 × 2 cm) with an oval morphology, extended right to the back of the external ear canal, well cleaved and separated from the mastoid bone cortex, characterized by the predominant calcific component. The mastoid cells had a normal pneumatization. There were no obvious abnormalities of the middle and internal ear structures bilaterally. It was decided the removal of the neoformation with a simple dissection. A written informed consent for the use of anonymous data, eventually for a future study, with the informed consent for the biopsy/operation, were obtained from the patient. During the operation it was confirmed that the mastoid bone cortex wasn’t involved.
Fig. 1

CT ear scan with coronal, sagittal and 3D reconstructions, with red circles pointing the location and the extension of the neoformation.

CT ear scan with coronal, sagittal and 3D reconstructions, with red circles pointing the location and the extension of the neoformation. On histological examination, in all the preparations prepared with hematoxylin-eosin staining, the sections are represented by a nodular lesion composed by a proliferation of rounded or fusiform cellular elements with leptochromatic nucleus. The cytoplasm is described as a poorly eosinophilic, arranged to form solid nests and cords immersed in abundant collagenous and/or myxoid stroma, interposed in a mature irregularly shaped trabecular bone, mainly located on the periphery of the lesion. Also spots of calcification and some small dilated vessels were present. There were absence of mitosis and areas of necrosis(Fig. 2). The above cellular elements were positive with immunohistochemical staining for S100 protein and vimentin and negative with immunohistochemical staining for Pan-CK, CK7, CK20 and EMA. The proliferation index assessed with Ki-67, is approximately is 1%. Two years after the diagnosis and the removal of the tumor there hasn’t been any relapse or metastasis, in accordance with the prognosis of a typical variant OFMT. The patient is in good condition, without any symptoms or pathological conditions related to the OFMT.
Fig. 2

Histologic preparation: Fusiform cellular elements, eosinophilic cytoplasm. Note the mature irregularly shaped trabecular bone, mainly on the periphery of the lesion.

Histologic preparation: Fusiform cellular elements, eosinophilic cytoplasm. Note the mature irregularly shaped trabecular bone, mainly on the periphery of the lesion.

Discussion

OFMT is a soft tissue tumor of uncertain histogenesis, which occurs more often in adults, with a higher incidence in males than females. Differential diagnosis includes myositis ossificans, ossifying hematoma, tumoral calcinosis, extraskeletal chondroma, low-grade fibromyxoid sarcoma, synovial sarcoma and extraskeletal or parosteal osteosarcoma [9]. Typically, OFMT presents as a slow-growing benign mass, nevertheless Graham et al. [6] confirmed the existence of malignant OFMT using immunohistochemistry and gene expression profiling, suggesting also that this tumor has a scrambled phenotype. Miettinen M et al. [7] evaluating malignancy parameters found that an increased mitotic activity, is a risk factor of local recurrences, whilst tumor size and necrosis are not significant risk factors. Folpe AL, Weiss SW [4] demonstrated that hypercellularity, nuclear atypia and high mitotic index activity (>2/50 HPFs), represent risk factors for aggressive behaviour with local recurrences and metastases, characteristics of the malignant variant, when low nuclear grade, low cellularity and a mitotic rate of <2/50 HPF,are the features of a typical variant. Cases that deviate from typical OFMT but do not meet malignant criteria can be designated as atypical OFMT. In immunohistochemistry the positivity expression level of S-100 protein tends to decrease as the tumor grade increases: 88% for typical cases, 75% for atypical cases, and 42% for malignant cases [6]. Involvement of the head and neck area is infrequent (10% to 15%) and intraoral presentation is very rare [10,11]. Nevertheless, tumor locations such as the oral cavity, mandibular gingival, tongue, etmoid sinus and other sites of the head and neck region have been described in the literature [11].

Conclusion

In conclusion, we present a case of a typical variant OFMT that occurred in an extremely unusual site, in the retroauricular perimastoid region. Considering that it is extremely rare, and the possibility of local metastasis especially for the malignant type, we believe that more studies are required for this “enigmatic” tumor which displays an uncertain line of differentiation, rendering the differential diagnosis a true challenge.

Conflict of interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Sources of funding

The L’Aquila University (Universita degli studi di L’Aquila).

Ethical approval

In Italy Ethics Committee stands for Institutional Review Board. This should be applied indeed for patients, but for studies such as clinical trials, invasive and/or experimental therapies. Since our paper is a case report there wasn’t any Ethics Committee approval. Instead there was a written and signed consent from the patient for the operation and for the use of anonymous data eventually for research.

Consent

There was a written and signed consent from the patient for the operation and for the use of anonymous data eventually for research.

Author contribution

Dr. Theodoros Varakliotis: Design, acquisition and analysis of data, drafting and revision of the manuscript, Prof. Gianluca Bellocchi: Supervision, revision of the manuscript Prof. Alberto Eibenstein: Supervision, revision of the manuscript Dr. Gilberto Acquaviva: technical support Dr. Francesco Casorati: technical support, collection of the data

Guarantor

THEODOROS VARAKLIOTIS
  11 in total

Review 1.  Ossifying fibromyxoid tumor of head and neck region: case report and systematic review of literature.

Authors:  Athena Kondylidou-Sidira; Athanassios Kyrgidis; Helias Antoniades; Konstantinos Antoniades
Journal:  J Oral Maxillofac Surg       Date:  2010-10-14       Impact factor: 1.895

2.  Atypical ossifying fibromyxoid tumor unusually located in the mediastinum: report of a case showing mosaic loss of INI-1 expression.

Authors:  Shogo Tajima; Kenji Koda
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

3.  Ossifying fibromyxoid tumor: a study of 6 cases of atypical and malignant variants.

Authors:  Kossivi Dantey; Karen Schoedel; Oleksandr Yergiyev; Richard McGough; Alka Palekar; Uma N M Rao
Journal:  Hum Pathol       Date:  2016-11-02       Impact factor: 3.466

4.  Ossifying fibromyxoid tumor of soft parts: a clinicopathologic, proteomic, and genomic study.

Authors:  Rondell P D Graham; Sarah Dry; Xinmin Li; Scott Binder; Armita Bahrami; Susana C Raimondi; Ahmet Dogan; Subhankar Chakraborty; Joshua J Souchek; Andrew L Folpe
Journal:  Am J Surg Pathol       Date:  2011-11       Impact factor: 6.394

Review 5.  Ossifying Fibromyxoid Tumor of the Retromolar Trigone: A Case Report and Systematic Review of the Literature.

Authors:  Savvas Titsinides; Nikolaos G Nikitakis; Jason Tasoulas; Argyriοs Daskalopoulos; Lampros Goutzanis; Alexandra Sklavounou
Journal:  Int J Surg Pathol       Date:  2017-04-24       Impact factor: 1.271

Review 6.  Ossifying fibromyxoid tumor resembling parosteal osteosarcoma.

Authors:  A Ogose; H Otsuka; T Morita; H Kobayashi; Y Hirata
Journal:  Skeletal Radiol       Date:  1998-10       Impact factor: 2.199

7.  Ossifying fibromyxoid tumor of soft parts--a clinicopathologic and immunohistochemical study of 104 cases with long-term follow-up and a critical review of the literature.

Authors:  Markku Miettinen; Val Finnell; John F Fetsch
Journal:  Am J Surg Pathol       Date:  2008-07       Impact factor: 6.394

8.  Ossifying fibromyxoid tumour of the neck clinically mimicking a primary neoplasm of the thyroid gland.

Authors:  S F Lax; M Ratschek; P Steindorfer; W Langsteger; D Harms; A Beham
Journal:  Pathol Res Pract       Date:  1995-02       Impact factor: 3.250

Review 9.  Ossifying fibromyxoid tumor of soft parts: a clinicopathologic study of 70 cases with emphasis on atypical and malignant variants.

Authors:  Andrew L Folpe; Sharon W Weiss
Journal:  Am J Surg Pathol       Date:  2003-04       Impact factor: 6.394

10.  The SCARE Statement: Consensus-based surgical case report guidelines.

Authors:  Riaz A Agha; Alexander J Fowler; Alexandra Saeta; Ishani Barai; Shivanchan Rajmohan; Dennis P Orgill
Journal:  Int J Surg       Date:  2016-09-07       Impact factor: 6.071

View more
  1 in total

1.  Ossifying fibromyxoid tumor of soft tissue: A case report with review of literature.

Authors:  Ahlem Bchir; Ahlem Bellalah; Nouha Ben Abdeljelil; Manel Njima; Leila Njim; Abdelfateh Zakhama; Rym Hadhri
Journal:  Ann Med Surg (Lond)       Date:  2021-06-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.